Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CNR1 | P21554 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7652554 | 0.90 | NPC1 (0.58) | NPC1ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL15145860 | 0.86 | CA1 (0.51) | NPC1ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL15584912 | 0.84 | CA1 (0.50) | L3MBTL1GAACA1CA2CA12 | |
| SCHEMBL15145784 | 0.84 | MEN1 (0.51) | NPC1ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL2246419 | 0.84 | CA1 (0.56) | MEN1KMT2AGAACA1CA2 | |
| SCHEMBL13884422 | 0.83 | CA1 (0.49) | ALDH1A1MEN1KMT2AL3MBTL1GAA | |
| SCHEMBL16192927 | 0.83 | NPC1 (0.52) | NPC1ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL13154744 | 0.82 | TPSAB1 (0.50) | L3MBTL1GAACA1CA2CA12 | |
| SCHEMBL15145793 | 0.82 | L3MBTL1 (0.55) | NPC1ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL1294826 | 0.82 | HTT (0.50) | NPC1RAB9AMEN1KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062007-B2 | Cyclic amide BACE-1 inhibitors having a benzamide substituent | MERCK SHARP & DOHME CORP. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140128361-A1 | CYCLIC AMIDE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-8623867-B2 | Cyclic amine BACE-1 inhibitors having a benzamide substituent | MERCK SHARP & DOHME CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130004518-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | Merck, Sharp & Dohme Corp. (US) | 2013-01-03 | — | — | US | disclosed |
| US-8278334-B2 | Cyclic amine BACE-1 inhibitors having a benzamide substituent | Merck, Sharp & Dohme Corp. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100152138-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | SCHERING CORP. | 2010-06-17 | — | — | US | disclosed |
| US-7662816-B2 | Cyclic amine BACE-1 inhibitors having a benzamide substituent | SCHERING CORPORATION (US) | 2010-02-16 | — | — | US | disclosed |
| EP-1660443-B1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | SCHERING CORP (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-1660443-A2 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | SCHERING CORPORATION (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050119227-A1 | Cyclic amine bace-1 inhibitors having a benzamide substituent | SCHERING CORPORATION | 2005-06-02 | — | — | US | disclosed |
| WO-2005016876-A2 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | SCHERING CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128361-A1 | CYCLIC AMIDE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | BACE1, BACE2, BCHE | NPC1 49/4885ALDH1A1 1387/4885RAB9A 2465/4885 |
| US-20100152138-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | BACE1, BACE2, BCHE | NPC1 47/4885ALDH1A1 1302/4885RAB9A 2585/4885 |
| US-20050119227-A1 | Cyclic amine bace-1 inhibitors having a benzamide substituent | BACE1, BACE2, BCHE | NPC1 47/4885ALDH1A1 1302/4885RAB9A 2585/4885 |
| US-20130004518-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | BACE1, BACE2, BCHE | NPC1 47/4885ALDH1A1 1302/4885RAB9A 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.